Kim Kyung-Hee, Pereira Naveen L
Division of Cardiology, Incheon Sejong General Hospital, Incheon, Korea.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Korean Circ J. 2021 Oct;51(10):797-836. doi: 10.4070/kcj.2021.0154. Epub 2021 Jul 22.
Genetics has played an important role in the understanding of different cardiomyopathies, and the field of heart failure (HF) genetics is progressing rapidly. Much research has also focused on distinguishing markers of risk in patients with cardiomyopathy using genetic testing. While these efforts currently remain incomplete, new genomic technologies and analytical strategies provide promising opportunities to further explore the genetic architecture of cardiomyopathies, afford insight into the early manifestations of cardiomyopathy, and help define the molecular pathophysiological basis for cardiac remodeling. Cardiovascular physicians should be fully aware of the utility and potential pitfalls of incorporating genetic test results into pre-emptive treatment strategies for patients in the preliminary stages of HF. Future work will need to be directed towards elucidating the biological mechanisms of both rare and common gene variants and environmental determinants of plasticity in the genotype-phenotype relationship. This future research should aim to further our ability to identify, diagnose, and treat disorders that cause HF and sudden cardiac death in young patients, as well as prioritize improving our ability to stratify the risk for these patients prior to the onset of the more severe consequences of their disease.
遗传学在理解不同类型的心肌病方面发挥了重要作用,心力衰竭(HF)遗传学领域正在迅速发展。许多研究还集中于通过基因检测来区分心肌病患者的风险标志物。虽然目前这些努力仍未完成,但新的基因组技术和分析策略为进一步探索心肌病的遗传结构、深入了解心肌病的早期表现以及帮助确定心脏重塑的分子病理生理基础提供了有前景的机会。心血管内科医生应充分认识到将基因检测结果纳入HF早期患者的预防性治疗策略中的效用和潜在陷阱。未来的工作需要致力于阐明罕见和常见基因变异的生物学机制以及基因型-表型关系中可塑性的环境决定因素。这项未来研究应旨在进一步提高我们识别、诊断和治疗导致年轻患者HF和心源性猝死的疾病的能力,以及优先提高我们在这些患者疾病出现更严重后果之前对其风险进行分层的能力。